WO1995034650A3 - Mn gene and protein - Google Patents

Mn gene and protein Download PDF

Info

Publication number
WO1995034650A3
WO1995034650A3 PCT/US1995/007628 US9507628W WO9534650A3 WO 1995034650 A3 WO1995034650 A3 WO 1995034650A3 US 9507628 W US9507628 W US 9507628W WO 9534650 A3 WO9534650 A3 WO 9534650A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
gene
polypeptides
nucleic acid
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/007628
Other languages
French (fr)
Other versions
WO1995034650A9 (en
WO1995034650A2 (en
Inventor
Jan Zavada
Silvia Pastorekova
Jaromir Pastorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Virology (Slovak Academy of Science)
Bayer Corp
Original Assignee
Institute of Virology (Slovak Academy of Science)
Ciba Corning Diagnosys Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/260,190 external-priority patent/US6774117B1/en
Priority claimed from US08/486,756 external-priority patent/US5981711A/en
Priority claimed from US08/481,658 external-priority patent/US5955075A/en
Priority claimed from US08/485,862 external-priority patent/US5989838A/en
Priority claimed from US08/485,863 external-priority patent/US6093548A/en
Priority claimed from US08/487,077 external-priority patent/US6069242A/en
Priority claimed from US08/485,049 external-priority patent/US6204370B1/en
Priority to DE69534246T priority Critical patent/DE69534246T2/en
Priority to EP95923907A priority patent/EP0763110B9/en
Priority to AU28616/95A priority patent/AU2861695A/en
Application filed by Institute of Virology (Slovak Academy of Science), Ciba Corning Diagnosys Corp filed Critical Institute of Virology (Slovak Academy of Science)
Priority to CA2192678A priority patent/CA2192678C/en
Priority to JP1996502486A priority patent/JP3977416B6/en
Priority to AT95923907T priority patent/ATE296883T1/en
Publication of WO1995034650A2 publication Critical patent/WO1995034650A2/en
Publication of WO1995034650A3 publication Critical patent/WO1995034650A3/en
Publication of WO1995034650A9 publication Critical patent/WO1995034650A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A complete genomic sequence including a full-length cDNA sequence for the MN gene, a putative oncogene, is disclosed, as well as proteins/polypeptides encoded thereby. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are also provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and preneoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression, and polymerase chain reaction (PCR) assays to detect genetic rearrangements in MN genes.
PCT/US1995/007628 1994-06-15 1995-06-15 Mn gene and protein Ceased WO1995034650A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT95923907T ATE296883T1 (en) 1994-06-15 1995-06-15 MN GENE AND PROTEIN
JP1996502486A JP3977416B6 (en) 1994-06-15 1995-06-15 MN gene and MN protein
CA2192678A CA2192678C (en) 1994-06-15 1995-06-15 Mn gene and protein
DE69534246T DE69534246T2 (en) 1994-06-15 1995-06-15 MN GENE AND PROTEIN
AU28616/95A AU2861695A (en) 1994-06-15 1995-06-15 Mn gene and protein
EP95923907A EP0763110B9 (en) 1994-06-15 1995-06-15 Mn gene and protein

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US08/260,190 US6774117B1 (en) 1992-03-11 1994-06-15 MN gene and protein
US08/260,190 1994-06-15
US44750495A 1995-06-07 1995-06-07
US08/485,049 US6204370B1 (en) 1992-03-11 1995-06-07 MN gene and protein
US08/485,863 1995-06-07
US08/481,658 1995-06-07
US08/487,077 US6069242A (en) 1992-03-11 1995-06-07 MN gene and protein
US08/486,756 1995-06-07
US08/485,863 US6093548A (en) 1992-03-11 1995-06-07 Detection and quantitation of MN-specific antibodies.
US08/447,504 1995-06-07
US08/485,862 US5989838A (en) 1992-03-11 1995-06-07 Immunological methods of detecting MN proteins and MN polypeptides
US08/481,658 US5955075A (en) 1992-03-11 1995-06-07 Method of inhibiting tumor growth using antibodies to MN protein
US08/486,756 US5981711A (en) 1992-03-11 1995-06-07 MN-specific antibodies and hybridomas
US08/485,049 1995-06-07
US08/487,077 1995-06-07
US08/485,862 1995-06-07

Publications (3)

Publication Number Publication Date
WO1995034650A2 WO1995034650A2 (en) 1995-12-21
WO1995034650A3 true WO1995034650A3 (en) 1996-02-15
WO1995034650A9 WO1995034650A9 (en) 1996-02-22

Family

ID=27575294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/007628 Ceased WO1995034650A2 (en) 1994-06-15 1995-06-15 Mn gene and protein

Country Status (3)

Country Link
AU (1) AU2861695A (en)
CA (1) CA2192678C (en)
WO (1) WO1995034650A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572891B2 (en) 2000-02-14 2009-08-11 The Regents Of The University Of California Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
US8378084B2 (en) 2006-12-22 2013-02-19 The Regents Of The University Of California Fusion molecule based on novel TAA variant

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6297041B1 (en) 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
JP3910798B2 (en) * 1998-10-23 2007-04-25 インスティトゥート オブ ヴァイロロジー MN gene and protein
US7713704B1 (en) 1998-10-23 2010-05-11 Institute Of Virology Of The Slovak Academy Of Science MN gene and protein
US7910691B2 (en) 1999-10-22 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US6902890B1 (en) 1999-11-04 2005-06-07 Diadexus, Inc. Method of diagnosing monitoring, staging, imaging and treating cancer
AR036833A1 (en) * 2001-10-18 2004-10-06 Bayer Corp HUMAN ANTIBODIES THAT JOIN MN AND HAVE NEUTRALIZING ACTIVITY OF CELLULAR ADHESION.
US7910549B2 (en) 2001-12-13 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
EP2508596B1 (en) 2002-02-21 2015-08-12 Institute Of Virology MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
DK3031910T3 (en) 2002-02-21 2017-10-23 Inst Virology MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE
EP1501939B1 (en) * 2002-04-16 2009-07-22 The Regents of The University of California Methods or renal cell carcinoma prognosis and treatment selection with carbonic anhydrase ix
CA2691447A1 (en) 2002-11-26 2004-06-10 Institute Of Virology Ca ix-specific inhibitors
AU2005241093B2 (en) 2004-05-04 2008-06-05 Institute Of Virology Of Slovak Academy Of Sciences MN/CA IX/ CA9 and renal cancer prognosis
EP2076611A4 (en) 2006-10-12 2010-08-25 Inst Virology SPRAY VARIANTS MN / CA9
US7820159B2 (en) 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
US8097423B2 (en) 2007-07-30 2012-01-17 Institute Of Virology MN/CA IX and breast cancer therapy
CA2901531C (en) 2013-02-22 2022-03-29 Wilex Ag Caix stratification based cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018152A1 (en) * 1992-03-11 1993-09-16 Ciba Corning Diagnostics Corp. Mn gene and protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018152A1 (en) * 1992-03-11 1993-09-16 Ciba Corning Diagnostics Corp. Mn gene and protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J.PASTOREK ET AL.: "Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment", ONCOGENE, vol. 9, no. 10, pages 2877 - 2888 *
M.A.FROHMAN ET AL.: "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, WASHINGTON US, pages 8998 - 9002 *
S.PASTOREKOVÁ ET AL.: "A novel quasi-viral agent, MaTu, is a two-component system", VIROLOGY, vol. 187, no. 2, ORLANDO US, pages 620 - 626 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572891B2 (en) 2000-02-14 2009-08-11 The Regents Of The University Of California Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
US8741306B2 (en) 2000-02-14 2014-06-03 The Regents Of The University Of California Kidney specific tumor vaccine directed against kidney tumor antigen G-250
US9409965B2 (en) 2000-02-14 2016-08-09 The Regents Of The University Of California Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
US10035981B2 (en) 2000-02-14 2018-07-31 The Regents Of The University Of California Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
US8378084B2 (en) 2006-12-22 2013-02-19 The Regents Of The University Of California Fusion molecule based on novel TAA variant
US9322010B2 (en) 2006-12-22 2016-04-26 The Regents Of The University Of California Fusion molecule based on novel TAA variant
US9492520B2 (en) 2006-12-22 2016-11-15 The Regents Of The University Of California Fusion molecule based on novel TAA variant

Also Published As

Publication number Publication date
CA2192678A1 (en) 1995-12-21
MX9606402A (en) 1998-10-31
AU2861695A (en) 1996-01-05
CA2192678C (en) 2010-12-14
WO1995034650A2 (en) 1995-12-21

Similar Documents

Publication Publication Date Title
WO1995034650A3 (en) Mn gene and protein
CA2131826A1 (en) MN Gene and Protein
JP2004512022A5 (en)
JP2007114212A (en) Compounds for prostate cancer immunodiagnosis and methods of use thereof
CA2269634A1 (en) Reagents and methods useful for detecting diseases of the breast
SE9500023D0 (en) Method of detecting cancer
CA2362527A1 (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
ES2217541T3 (en) DIAGNOSIS OF ABNORMALITIES IN EPITHELIAL CELLS.
JP2001521744A5 (en)
JP2005507648A5 (en)
WO2001032702B1 (en) Molecular structure of rhd negative locus
CA2287571A1 (en) Reagents and methods useful for detecting diseases of the prostate
CA2232237A1 (en) Reagents and methods useful for detecting diseases of the breast
EP2573169B1 (en) Cartilage-specific hif-2 transgenic mouse as an animal model for arthritis, and use thereof
CA2368802A1 (en) Mutations associated with iron disorders
WO1999037764A3 (en) New members of the glypican gene family
CA2318486A1 (en) Novel nucleic acid molecules correlated with the rhesus weak d phenotype
KR100902282B1 (en) Diabetes Diagnosis Composition, Diabetes Diagnosis Kit and Diabetes Diagnosis Method
KR101878974B1 (en) Composition and method for detecting a diagnostic marker for renal cell carcinoma
US20070264651A1 (en) Methods, compositions, and kits for the detection and monitoring of kidney cancer
JP5467256B2 (en) Gastrointestinal cancer detection serum tumor marker, digestive cancer detection kit, and digestive cancer detection method
CA2370519A1 (en) Nucleic acids encoding a mutt domain-containing polypeptide
US7160697B2 (en) Use of novel cytokine receptors as biomarkers and therapeutic targets in human cancer
GB2371548A (en) Sequences encoding human neoplastic marker
US20030109001A1 (en) Process for the recombinant production of ribonucleoproteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 17,23 AND 24, DESCRIPTION, REPLACED BY NEW PAGES BEARING THE SAME NUMBER;AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2192678

Country of ref document: CA

Ref document number: 1995923907

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/1996/006402

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1995923907

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1995923907

Country of ref document: EP